NLRP3 and type 2 diabetes mellitus: NLRP3 inflammasome activation is implicated in an array of inflammatory pathobiologies {reviewed in [(Coll et al., 2022), (Hutton et al., 2016)]}, including Alzheimer’s disease (Saresella et al., 2016; Heneka et al., 2013; Venegas et al., 2017), cryopyrin-associated periodic syndrome (Leslie et al., 2006; Lachmann et al., 2009), type 2 diabetes (Masters et al., 2010; Lei et al., 2019), and both acute and chronic kidney diseases (Lei et al., 2019; Vilaysane et al., 2010; Ludwig-Portugall et al., 2016).